top of page
Home
Technology
Pipeline
Female Stress Urinary Incontinence
About Us
Open Positions
Investors & Media
Contact
More...
Use tab to navigate through the menu items.
ALL POSTS
PUBLICATIONS
AWARDS
NEWS
MEDIA
RESOURCES
Search
Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...
Muvon
Jul 1
2 min read
MUVON Therapeutics is Tackling Taboos in Women's Health
In our lates video produced by Innovation Zurich , MUVON's CEO, Deana Mohr, shares, among other things, how the Zurich-based spin-off...
Muvon
Apr 30
1 min read
MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025
Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...
Muvon
Apr 16
2 min read
INVEST IN OUR
INNOVATION
MORE INFORMATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page
